Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 738

Terahertz biosensor detects skin cancer with remarkable accuracy, advancing new era of early detection

Researchers have developed a revolutionary biosensor using terahertz (THz) waves that can detect skin cancer with exceptional sensitivity, potentially paving the way for earlier and easier diagnoses. Published in IEEE Transactions on Biomedical Engineering, the study presents a significant advancement in early cancer detection, thanks to the collaboration of multidisciplinary teams from Queen Mary University of London and the University of Glasgow.

“Traditional methods for detecting skin cancer often involve expensive, time-consuming, CT, PET scans and invasive higher frequencies technologies,” explains Dr. Shohreh Nourinovin, Postdoctoral Research Associate at Queen Mary’s School of Electronic Engineering and Computer Science, and the study’s first author. “Our biosensor offers a non-invasive and highly efficient solution, leveraging the unique properties of THz waves—a type of radiation with lower energy than X-rays, thus safe for humans—to detect subtle changes in cell characteristics.”

The key innovation lies in the biosensor’s design. Featuring tiny, asymmetric resonators on a flexible substrate, it can detect subtle changes in the properties of cells. Unlike traditional methods that rely solely on , this device analyzes a combination of parameters, including , transmission magnitude, and a value called “full width at half maximum” (FWHM). This comprehensive approach provides a richer picture of the tissue, allowing for more accurate differentiation between healthy and cancerous cells and to measure malignancy degree of the tissue.

Gene Therapy in Mice Holds Promise for ALS and Dementia

Neuroresearchers at Macquarie University in Australia say they have developed a single-dose genetic medicine that has halted the progression of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) in mice. The team, which believes its approach may even offer the potential to reverse some of the effects of the fatal diseases, thinks it may also hold opportunities for treating more common forms of dementia, such as Alzheimer’s disease.

The new treatment, dubbed CTx1000, targets pathological build-ups of the protein TDP-43 in cells in the brain and spinal cord, which has been associated with ALS, FTD, and other forms of dementia. The scientists, led by Lars Ittner, PhD, hope to see CTx1000 begin human clinical trials in as little as two years. Their study “Targeting 14–3-3?-mediated TDP-43 pathology in amyotrophic lateral sclerosis and frontotemporal dementia mice” appears in Neuron.

“Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are characterized by cytoplasmic deposition of the nuclear TAR-binding protein 43 (TDP-43). Although cytoplasmic re-localization of TDP-43 is a key event in the pathogenesis of ALS/FTD, the underlying mechanisms remain unknown. Here, we identified a non-canonical interaction between 14–3-3θ and TDP-43, which regulates nuclear-cytoplasmic shuttling,” wrote the investigators.

“Genomic Time Machine” Reveals Secrets of Human DNA

The human genome, a complex mosaic of genetic data essential for life, has proven to be a treasure trove of strange features. Among them are segments of DNA that can “jump around” and move within the genome, known as “transposable elements” (TEs).

As they change their position within the genome, TEs can potentially cause mutations and alter the cell’s genetic profile but also are master orchestrators of our genome’s organization and expression. For example, TEs contribute to regulatory elements, transcription factor binding sites, and the creation of chimeric transcripts – genetic sequences created when segments from two different genes or parts of the genome join together to form a new, hybrid RNA molecule.

Matching their functional importance, TEs have been recognized to account for half of the human DNA. However, as they move and age, TEs pick up changes that mask their original form. Over time, TEs “degenerate” and become less recognizable, making it difficult for scientists to identify and track them in our genetic blueprint.

Junk DNA in birds may hold key to safe, efficient gene therapy

The recent approval of a CRISPR-Cas9 therapy for sickle cell disease demonstrates that gene editing tools can do a superb job of knocking out genes to cure hereditary disease. But it’s still not possible to insert whole genes into the human genome to substitute for defective or deleterious genes.

A new technique that employs a retrotransposon from birds to insert genes into the genome holds more promise for , since it inserts genes into a “safe harbor” in the human genome where the insertion won’t disrupt essential genes or lead to cancer.

Retrotransposons, or retroelements, are pieces of DNA that, when transcribed to RNA, code for enzymes that copy RNA back into DNA in the genome—a self-serving cycle that clutters the genome with retrotransposon DNA. About 40% of the human genome is made up of this “selfish” new DNA, though most of the genes are disabled, so-called junk DNA.

‘All of Us’ reports half of the genomes it has sequenced are from non-Europeans

Although people of European descent account for less than one-quarter of the world’s population, their DNA disproportionately drives genetics research. Between 2005 and 2018, the majority of genome-wide association studies were conducted with data from people living in just three countries — the United Kingdom, the United States, and Iceland.

“The paradox of precision medicine is that you have to have a ton of different kinds of people to figure out one person really well,” said Josh Denny, CEO of the All of Us research program. “There’s still so much we don’t understand about the human genome, especially about rare variation. Huge projects like ours are really helping to accelerate that understanding.”

All of Us has recruited more than 750,000 volunteers to provide survey responses about their health, medical records, and if they’re willing, biological samples for molecular and genetic testing. Genetic data from some participants have been available for researchers since 2020, but the new release this week includes the whole genome sequences of nearly 250,000 participants — half of whom are of non-European ancestry.

Treating liver cancer with microrobots piloted by a magnetic field

Canadian researchers led by Montreal radiologist Gilles Soulez have developed a novel approach to treat liver tumors using magnet-guided microrobots in an MRI device.

The idea of injecting microscopic robots into the bloodstream to heal the human body is not new. It’s also not science fiction. Guided by an , miniature biocompatible robots, made of magnetizable iron oxide nanoparticles, can theoretically provide in a very targeted manner.

Until now, there has been a technical obstacle: the force of gravity of these microrobots exceeds that of the magnetic force, which limits their guidance when the tumor is located higher than the injection site. While the magnetic field of the MRI is high, the magnetic gradients used for navigation and to generate MRI images are weaker.

A Sprinkle of Gold Dust Could Help Reverse Symptoms of Parkinson’s Disease

Scientists are investigating whether an oral drug sprinkled with gold nanoparticles could one day treat neurodegenerative diseases like Parkinson’s and multiple sclerosis.

The experimental medicine, called CNM-Au8, has now shown success in boosting the brain’s metabolism in phase II clinical trials.

Research on the safety and efficacy of the daily drug is still ongoing, but the initial results have researchers hopeful. The medicine contains suspended nanoparticles of gold that can apparently pass the blood-brain barrier and improve energy supply to neurons, preventing their decline.

Elon Musk shares update on Neuralink’s first human patient

Elon Musk shared an update on Neuralink’s first human patient and their experience with the N1 chip.

The first human Neuralink patient seems to have made a full recovery with no ill effects and is able to control the mouse around the screen just by thinking, said Elon Musk during an apparent on X Spaces.

Musk added that Neuralink continuously observes the patient’s ability to use the N1 brain implant. The patient is currently tasked to click on the mouse button as often as possible.

New technique for revealing genetic repeats yields surprising insights into Huntington’s disease

Neurodegenerative diseases are among the most complex human ailments, and their exact causes and mechanisms are the subject of ongoing research and debate. When it comes to Huntington’s disease, steadily accumulating evidence over the past 30 years has led to a model of molecular events that explains several key features of the disease, including why it has an earlier onset in some people and why it causes symptoms such as involuntary movements and mood swings.

But two new complementary papers from The Rockefeller University suggest that this may not be the whole story.

Huntington’s is caused by somatic CAG expansions in which a triplet repeat of DNA bases in a mutated Huntingtin (mHTT) gene increase in number throughout life, leading to . As described in Nature Genetics and in Neuron, the Rockefeller scientists used a custom technique to reveal that these genetic repeats are unstable, and likely producing more toxic proteins, only in select brain . Moreover, some cells they studied proved surprisingly resilient to CAG repeat expansion.

/* */